It’s an unknown what drives the the market’s view on a valuation of the group. Vifor is less than 10% and is likely to become a smaller part as Behring is dominant and growing faster. I don’t think you can definitively say that Vifor has materially detracted the growth prospects of the group. And it remains accretive on current multiples.
recent Ferrinject approval , and now reimbursement , in China is potentially huge. An enormous population of iron deficient patients.
It’s an unknown what drives the the market’s view on a valuation...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$289.29 |
Change
0.680(0.24%) |
Mkt cap ! $139.9B | |||
| Open | High | Low | Value | Volume |
| $287.64 | $289.70 | $287.16 | $127.0M | 437.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 21 | $289.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $289.26 | 33 | 1 |
View Market Depth
| Last trade - 15.40pm 04/10/2024 (20 minute delay) ? |
| CSL (ASX) Chart |